Advertisement

Annals of Hematology

, Volume 95, Issue 9, pp 1561–1562 | Cite as

Klebsiella pneumoniae primary liver abscess associated with ruxolitinib

  • Yoshiharu KusanoEmail author
  • Yasuhito Terui
  • Kyoko Ueda
  • Kiyohiko Hatake
Open Access
Letter to the Editor

Keywords

Primary myelofibrosis Ruxolitinib Pyogenic liver abscess 

Dear Editor,

Pyogenic liver abscess is an uncommon intra-abdominal infection associated with high mortality. The liver is in contact with massive quantities of blood from systemic and portal circulation. Therefore, any breakdown of its immune system can directly cause lethal infections. Patients with Klebsiella pneumoniae primary liver abscess (KPPLA) have higher incidences of diabetes or glucose intolerance compared to those with other pyogenic liver abscess, but it is unknown how diabetes influences the liver’s immunity including Kupffer’s cells. Here, we present a case with primary myelofibrosis (PMF) suffering from KPPLA during the course of ruxolitinib, a JAK1 and JAK2 inhibitor.

A 78-year-old man had a diagnosis of JAK2V617F+ PMF. Treatment with ruxolitinib 20 mg twice daily was initiated in May 2015. At the 2-month follow-up, he was suffering from herpes zoster and thrombocytopenia, so the dosage of ruxolitinib was reduced to 10 mg twice daily. Since dosage was reduced, absolute hemoglobin and thrombocyte counts had been stable. In January 2016, he presented with fatigue, fever with chills, and persistent right upper quadrant pain. Blood pressure was 91/50 mmHg, pulse was 120 beats per minute, respiratory rate was 26 breaths per minute, and oxygen saturation was 98 % while he was breathing a room air. A laboratory blood test showed elevated biliary and liver enzymes, prothrombin time (PT), activated partial thromboplastin time, and fibrinogen degradation products (FDP), whereas hemoglobin and platelets were decreased due to disseminated intravascular coagulopathy (DIC), which was score 4 based on DIC diagnostic criteria (systemic inflammatory response syndrome, platelet count of 8.5 × 104/μL, FDP > 10 μg/ml, and PT-international normalized ratio > 1.2). The absolute neutrophil count and immunoglobulin levels were normal. Abdominal contrast-enhanced computer tomography scans showed an abscess with a 5-cm radius (Fig. 1). Percutaneous catheter drainage of abscess was performed, and piperacillin-tazobactam 4.5 mg thrice daily was initiated. An alleviation of fever was observed from the next day, and the volume of the abscess dwindled considerably in 14 days. Klebsiella pneumoniae was detected from the pus. Magnetic resonance imaging did not reveal any predisposing intra-abdominal factors for abscess formation. The catheter was removed and the patient was discharged from hospital continuing on cefcapene 100 mg trice daily for another 3 weeks.
Fig. 1

a Liver abscess with a 5-cm radius before drainage. b Diminished abscess after 14-day catheter drainage

Ruxolitinib interferes with a variety of immune cells and their function [1, 2, 3]. In fact, the number and activity of immune cells were diminishing in our case: B cells, 28/μl; CD4 + T cells, 50/μl; CD8+ T cells, 53/μl; and NK-cell activity, 4 % (normal 18–40). With severe impairment of the number and activity of NK cells, JAK mutations and STAT deficiency can cause not only viral infection but also severe bacterial infections [4]. The defect in cell-mediated immunity combined with or without impaired function of B cells might be induced by ruxolitinib, which is thought to be associated with KPPLA.

ECOG, Eastern Cooperative Oncology Group; FDP, fibrinogen degradation products; JAK, Janus kinase; KPPLA, Klebsiella pneumoniae primary liver abscess; PMF, primary myelofibrosis; PT, prothrombin time; STAT, signal transducer and activator of transcription; DIC, disseminated intravascular coagulopathy

Notes

Acknowledgments

There are no specific acknowledgements.

Compliance with ethical standards

Funding

The authors declare that they have no funding.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75:2187–99CrossRefPubMedGoogle Scholar
  2. 2.
    Heine A, Held SA, Daecke SN, Wallner S, Yajananayana SP, Kurts C et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–202CrossRefPubMedGoogle Scholar
  3. 3.
    Parampalli Yajnanarayana S, Steobig T, Comez I, Alchalby H, Scheonberg K, Rudolph J et al (2015) JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Hematol 169:824–33CrossRefGoogle Scholar
  4. 4.
    O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Yoshiharu Kusano
    • 1
    Email author
  • Yasuhito Terui
    • 1
  • Kyoko Ueda
    • 1
  • Kiyohiko Hatake
    • 1
  1. 1.Department of Hematology and OncologyCancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations